Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Aug;9(8):1460-1468.
doi: 10.1002/2211-5463.12687. Epub 2019 Jul 3.

Identification of potential diagnostic biomarkers for Parkinson's disease

Affiliations

Identification of potential diagnostic biomarkers for Parkinson's disease

Fenghua Jiang et al. FEBS Open Bio. 2019 Aug.

Abstract

The identification of biomarkers for early diagnosis of Parkinson's disease (PD) prior to the onset of symptoms may improve the effectiveness of therapy. To identify potential biomarkers, we downloaded microarray datasets of PD from the Gene Expression Omnibus database. Differentially expressed genes (DEGs) between PD and normal control (NC) groups were obtained, and the feature selection procedure and classification model were used to identify optimal diagnostic gene biomarkers for PD. A total of 1229 genes (640 up-regulated and 589 down-regulated) were obtained for PD, and nine DEGs (PTGDS, GPX3, SLC25A20, CACNA1D, LRRN3, POLR1D, ARHGAP26, TNFSF14 and VPS11) were selected as optimal PD biomarkers with great diagnostic value. These nine DEGs were significantly enriched in regulation of circadian sleep/wake cycle, sleep and gonadotropin-releasing hormone signaling pathway. Finally, we examined the expression of GPX3, SLC25A20, LRRN3 and POLR1D in blood samples of patients with PD by qRT-PCR. GPX3, LRRN3 and POLR1D exhibited the same expression pattern as in our analysis. In conclusion, this study identified nine DEGs that may serve as potential biomarkers of PD.

Keywords: Parkinson's disease; biomarker; differentially expressed genes; integrated analysis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Identification of optimal gene biomarkers for PD. (A) The importance value of each DEG ranked according to the mean decrease in accuracy by using a random forest analysis. (B) The variance rate of classification performance when increasing numbers of the predictive DEGs. (C–K) Box‐plots displaying the expression levels of PTGDS (C), GPX3 (D), SLC25A20 (E), CACNA1D (F), LRRN3 (G), POLR1D (H), ARHGAP26 (I), TNFSF14 (J), and VPS11 (K); the y‐axis represents gene expression levels.
Figure 2
Figure 2
ROC results. (A–C) The ROC results of SVM (A), random forest (B) and decision tree (C) models based on the nine DEGs between PD and NCs. (D–F) The ROC results of SVM (D), random forest (E) and decision tree (F) models of the confirmation by dataset GSE72267 for these three models. The value before the parenthese represents the cut‐off. The values in the parenthese represent the specificity and sensitivity, respectively. The value below represents the AUC.
Figure 3
Figure 3
PPI network. The red and green ellipses represent proteins encoded by up‐ and down‐regulated differentially expressed mRNAs between PD and normal controls. Blue ellipses represent other proteins. Ellipses with a black border are the nine DEGs which were selected as the optimal diagnostic gene biomarkers for PD.
Figure 4
Figure 4
The qRTPCR results of DEGs between PD and NCs. (A) GPX3, (B) SLC25A20, (C) LRRN3, and (D) POLR1D. The P‐value > 0.05 was assessed by one‐way ANOVA. The error bars represent SD. n = 3.

Similar articles

Cited by

References

    1. Wirdefeldt K, Adami HO, Cole P, Trichopoulos D and Mandel J (2011) Epidemiology and etiology of Parkinson's disease: a review of the evidence. Eur J Epidemiol 26 (Suppl 1), S1–S58. - PubMed
    1. Aarsland D, Creese B, Politis M, Chaudhuri KR, Ffytche DH, Weintraub D and Ballard C (2017) Cognitive decline in Parkinson disease. Nat Rev Neurol 13, 217–231. - PMC - PubMed
    1. Kalia LV and Lang AE (2015) Parkinson's disease. Lancet 386, 896–912. - PubMed
    1. Chen L, Yang J, Lu J, Cao S, Zhao Q and Yu Z (2018) Identification of aberrant circulating miRNAs in Parkinson's disease plasma samples. Brain Behav 8, e00941. - PMC - PubMed
    1. Chi J, Xie Q, Jia J, Liu X, Sun J, Deng Y and Yi L (2018) Integrated analysis and identification of novel biomarkers in Parkinson's disease. Front Aging Neurosci 10, 178. - PMC - PubMed

Associated data